ClinicalTrials.gg
RecruitingNCT07858591PsA-RETINAUpdated Oct 13, 2026

Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.

An observational study in Arthritic Psoriasis, Psoriasis (PsO) and Retinal Vessels, sponsored by Bursa Yuksek Ihtisas Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Bursa Yuksek Ihtisas Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 13, 2026Eligibility revisedDesign changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
135
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Arthritis, Psoriatic with a site in Turkey — 6 open to participants now, 10 under way, 4 of them phase 3. Arthritis, Psoriatic · Turkey.

Planned enrollment
4th of 15
135 · median 90
Started
2026
with 1 other
Observational
15 of 31
3 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Bursa Yuksek Ihtisas Training and Research Hospital

Among the 31 studies in Arthritis, Psoriatic with a site in Turkey, this one is the 4th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 31st registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

6 of the 31 studies in Arthritis, Psoriatic with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Arthritis, Psoriatic with a site in Turkey, or all of them as a file.
02

Study summary

In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye function, the dimensions of the foveal avascular zone (FAZ) supplied by this layer, and retinal vascular networks can be measured using non-invasive methods. OCTA (Optical Coherence Tomography Angiography) is an imaging tool that enables the non-invasive assessment of retinal microvascular densities and the measurement of the foveal avascular zone's dimensions. Studies conducted to date indicate that retinal capillary vessels and the dimensions of the foveal avascular zone are affected in rheumatological diseases, especially associated with systemic inflammation. This study aims to compare retinal capillary vessel density and foveal avascular zone dimensions in patients with psoriatic arthritis against those in a healthy population and in patients with psoriasis who do not have psoriatic arthritis, utilizing the non-invasive method of optical coherence tomography angiography.

Read the detailed description

In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Non-invasive methods allow for the measurement of-and the detection of changes in-the thickness of the choroid layer (which plays a crucial role in maintaining normal eye function), the foveal avascular zone (nourished by this layer), and the retinal vascular networks. OCTA (Optical Coherence Tomography Angiography) is an imaging tool capable of non-invasively assessing retinal microvascular densities and measuring the dimensions of the foveal avascular zone. Retinal microvascular structures can be affected by systemic pathologies, including various eye diseases. In recent years, there has been growing evidence indicating that retinal vessel densities-as detected by OCTA-are significantly altered and the dimensions of the foveal avascular zone differ in patients with connective tissue diseases, vasculitis, and spondylitis. Psoriatic arthritis is a common chronic inflammatory disease characterized by both spondyloarthropathy and peripheral arthritis involvement. There is currently no data in the literature regarding the status of the choroidal vasculature-a highly perfused tissue-in patients with psoriatic arthritis or its relationship with disease activity. In this study, we aimed to compare retinal capillary density and foveal avascular zone dimensions among patients with psoriatic arthritis, patients with psoriasis, and healthy individuals using OCTA. The study will also compare findings between subgroups of psoriatic patients with and without concomitant spondylitis.

03

Conditions studied

  • Arthritic Psoriasis
  • Psoriasis (PsO)
  • Retinal Vessels

Keywords

  • Psoriatic arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of volunteers from among patients with psoriatic arthritis who are being followed at the study center's rheumatology clinic. The patient control group comprises volunteers diagnosed with psoriasis by a specialist dermatologist. Participants in the healthy control group are healthcare workers or patient companions matched for age and gender with the patient group and the patient control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteers diagnosed with psoriatic arthritis according to CASPAR criteria
  • Volunteers diagnosed with psoriasis by a specialist dermatologist
  • Hospital staff or patient companions with no chronic illnesses

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Cancer
  • Pregnancy or lactation
  • Chronic renal failure
  • Glocome
  • History of eye surgery
  • History of eye trauma
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
135 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Psoriatic arthritis

    Participants with psoriatic arthritis

    Diagnostic Test: OCTA-SCP · Diagnostic Test: OCTA-DCP · Diagnostic Test: OCTA-RPC · Diagnostic Test: OCTA-FAZ

  • Psoriasis

    Psoriasis participants with no other known systemic inflammatory disease

    Diagnostic Test: OCTA-SCP · Diagnostic Test: OCTA-DCP · Diagnostic Test: OCTA-RPC · Diagnostic Test: OCTA-FAZ

  • Healthy controls

    Patient companions or hospital staff with no known chronic illnesses

    Diagnostic Test: OCTA-SCP · Diagnostic Test: OCTA-DCP · Diagnostic Test: OCTA-RPC · Diagnostic Test: OCTA-FAZ

Interventions

  • Diagnostic testOCTA-SCP

    Vessel density of retinal superficial capillary plexus

  • Diagnostic testOCTA-DCP

    Vessel density of retinal deep capillary plexus

  • Diagnostic testOCTA-RPC

    Vessel density of retinal prepapillary capillaries

  • Diagnostic testOCTA-FAZ

    FAZ essessment parameters

06

What researchers measure

Primary outcomes

  1. Retinal SCP, VD

    Vessel density of retinal superficial capillary plexus

    Time frame: 1 day

  2. Retinal DCP, VD

    Vessel density of retinal deep capillary plexus

    Time frame: 1 day

  3. Retinal RCP, VD

    Vessel density of retinal prepapillary capillaries

    Time frame: 1 day

  4. FAZ parameters

    Foveal avasculary assessment parameters

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
  • University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
    Bursa, Yıldırım 16130, Turkey (Türkiye)
    Recruiting
    • Koray Ayar · Contactayarkoray@hotmail.com · 05325618450
    • Koray Ayar, Associated Proffessor (Dr.) · Contactayarkoray@hotmail.com · +90 224-2955000
    • Koray Ayar, Associated Proffessor (Dr.) · Principal investigator
    • Neslihan Parmak Yener, Associated Proffessor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 77 non-industry observational studies under Arthritis, Psoriatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 20. This study's planned 11 months is below that.

Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Aug 20, 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital · Bursa, Turkey (Türkiye)
Show 1 removed
  • SBU Bursa Yüksek İhtisas EAH · Bursa, Turkey (Türkiye)
Oct 13, 2026
Eligibility
Revised
Oct 13, 2026
Contact
Study contact changed: a•••@hotmail.com · •••5000→a•••@hotmail.com · •••5000. See the current contact
Oct 13, 2026
Design
Study type Interventional→Observational
Oct 13, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 13, 2026
    1 site added, 1 site removed
    Show site
    • University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital · Bursa, Turkey (Türkiye)
    Show 1 removed
    • SBU Bursa Yüksek İhtisas EAH · Bursa, Turkey (Türkiye)
    Eligibility Revised
    Design Study type Interventional→Observational
    Contact Study contact changed: a•••@hotmail.com · •••5000→a•••@hotmail.com · •••5000. See the current contact
    + 2 other changes: arm descriptions and data sharing statement
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858591
Lead sponsor
Bursa Yuksek Ihtisas Training and Research Hospital
Responsible party
Koray Ayar (Associate Professor (Dr.), Saglik Bilimleri Universitesi) — Principal investigator
First posted
Oct 5, 2026
Start date
Sep 1, 2026
Primary completion
Aug 20, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Koray Ayar, Associated Proffessor
Contact
ayarkoray@hotmail.com
+90 224-2955000 ext. 1648

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion